Upon infection, mycobacteria, such as Mycobacterium tuberculosis (Mtb) and
nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering …

The emergence of drug resistance continues to afflict TB control where drug resistant strains
have become a global health concern. Contrary to drug-sensitive TB, the treatment of …

Abstract Background and Purpose Nitazoxanide is a therapeutic anthelmintic drug. Our
previous studies found that nitazoxanide and its metabolite tizoxanide activated adenosine …

Background Many treatments are being assessed for repurposing to treat coronavirus
disease 2019 (COVID-19). One drug that has shown promising results in vitro is …

The composition of the gastrointestinal microbiota influences systemic immune responses,
but how this affects infectious disease pathogenesis and antibiotic therapy outcome is poorly …

Development of novel anti-tuberculosis combination regimens that increase efficacy and
reduce treatment timelines will improve patient compliance, limit side-effects, reduce costs …

ABSTRACT A milestone in the development of novel antituberculosis drugs is the
demonstration of early bactericidal activity (EBA) in a phase IIa clinical trial. The significant …

Despite their therapeutic benefits, antibiotics exert collateral damage on the microbiome and
promote antimicrobial resistance. However, the mechanisms governing microbiome …

Drug repurposing is a feasible strategy in developing novel medications. Regarding the
cancer field, scientists are continuously making efforts to redirect conventional drugs into …

Background To address the emergence of SARS-CoV-2, multiple clinical trials in humans
were rapidly started, including those involving an oral treatment by nitazoxanide, despite no …